MEDIUM confidence: 100% data completeness, but the composite (55) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $46.4B— | $46.2B-0.5% | $45.0B-2.5% | $48.3B+7.3% | $48.2B-0.2% |
| EPS (dil.) | $3.12— | $2.95-5.4% | $3.86+30.8% | $-4.41-214.2% | $3.45n/m |
| Free Cash Flow | $15.2B— | $11.9B-21.6% | $12.7B+5.9% | $13.9B+10.2% | $12.8B-7.9% |
| Gross Margin | 57.7% | 57.4%-0.3pp | 56.3%-1.0pp | 56.8%+0.5pp | 71.1%+14.3pp |
| Operating Margin | 20.6% | 20.1%-0.5pp | 18.8%-1.3pp | 20.0%+1.2pp | 28.5%+8.5pp |
| Net Margin | 15.1% | 13.7%-1.4pp | 17.8%+4.1pp | -18.5%-36.4pp | 14.6%+33.2pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $69 (last qtr, 6 analysts) → $69 (last mo, 6) (+0.0%).
Buy-rated share 34% → 36% over ~3 months (+1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jul 2026 | $1.60 | $2.04 | +27.5% |
| Apr 2026 | $1.42 | $1.58 | +11.3% |
| Feb 2026 | $1.23 | $1.26 | +2.4% |
| Oct 2025 | $1.52 | $1.63 | +7.2% |
| Jul 2025 | $1.09 | $1.46 | +33.9% |
| Apr 2025 | $1.49 | $1.80 | +20.8% |
| Feb 2025 | $1.47 | $1.67 | +13.6% |
| Oct 2024 | $1.49 | $1.80 | +20.8% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$1.9M over 180 days (0 open-market buys, 2 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of -6.6%/yr (revenue basis).
Base free cash flow $13.1B (avg FY2023–FY2025; latest year $12.8B) · equity value $132.0B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 55 for Bristol-Myers Squibb indicates a neutral outlook, with the stock's strong profitability and momentum offset by lower growth and value scores. The company exhibits strong momentum, with a 12-month return of 38.5%, and scores high on profitability, driven by an ROE near 47%. However, its growth score is dragged down by negative revenue and free cash flow growth, and it trades at a P/E of 14.2, which is relatively in line with its peers. The long-term and short-term scores are closely aligned, suggesting a consistent outlook.